- •
There are data to suggest that an oligometastatic state may confer a better outcome than higher-volume metastases.
- •
Such patients may be considered for aggressive approaches, including radical treatment of the primary cancer.
- •
The definition of oligometastatic state remains contentious, and superior imaging is challenging the traditional paradigm based on conventional imaging.
- •
Nonrandomized data suggest a survival benefit for patients who undergo treatment of the primary despite metastatic disease
The Role of Local Therapy for Oligometastatic Prostate Cancer: Should We Expect a Cure?
Section snippets
Key points
Defining oligometastatic prostate cancer
Most studies and trials have defined oligometastasis in prostate cancer according to the number of metastatic lesions. Most vary between 3 and 5 metastases,2, 3, 4, 5, 6, 7, 8, 9, 11 although 1 study included patients with 10 or fewer lesions.12 Other studies have defined the oligometastatic state according to site of lesions, with lymph node, bone, and extrapelvic metastases commonly used as site-specific criteria.21 In addition, 1 previous study used the size of the metastases as part of
Surgical Treatment of Oligometastatic Prostate Cancer
It is important to remember that there is no level 1 evidence with respect to treatment of the primary in metastatic prostate cancer, and guidelines uniformly recommend systemic treatment as the standard of care. Data on treatment are drawn largely from nonrandomized trials, retrospective cohorts, and post-hoc analyses of prospective studies, all of which carry inherent bias, and should be interpreted with caution.
Nevertheless, there are some data that support the role of cytoreductive
Limitations of the evidence for treating the primary in oligometastatic disease
Although, at face value, the evidence for treatment of the primary in oligometastatic prostate cancer may be convincing, it must be interpreted with caution. There is currently no level 1 evidence from randomized trials suggesting that local treatment of the primary tumor in metastatic prostate cancer improves survival. Many of the studies are epidemiologic or are nonrandomized and therefore have significant methodological limitations (selection bias in particular), which limits the scope of
Imaging techniques in redefining metastatic disease
Traditional curative treatment of localized prostate cancer has only been advocated in the nonmetastatic setting.11 At present, the standard for staging prostate cancer, in order to determine eligibility for potentially curative treatment, is cross-sectional imaging (CT or MRI and technetium-99m [99mTc] bone scan or single-photon emission CT [SPECT]). However, over the past few years, significant advancements in imaging techniques have been made, specifically in PET imaging.45, 46, 47 Emerging
End points in oligometastatic prostate cancer: is a cure really expected?
Patients presenting with advanced prostate cancer account for approximately one-third of prostate cancer deaths in the United States, with an average age of 73 years and a median survival of approximately 3 years.55 However, most patients who die from prostate cancer are those who recur after radical treatment. Men with oligometastatic disease belong to both groups and accordingly, discussion of a cure may not adequately represent the complexity of the disease. It may be more appropriate to
Imaging in Oligometastatic Prostate Cancer
PSMA-targeted imaging is gaining interest, with data showing high sensitivity to small-volume sites of prostate cancer that are not detectable on conventional imaging.62 The ongoing proPSMA (Prospective Evaluation of 68Ga-PSMA–PET/CT for Recurrence Detection of Prostate Cancer and Its Impact on Patient Management) study, a single-arm, phase III imaging trial, is designed to prospectively evaluate the impact of 68Ga-PSMA–PET/CT on the therapeutic management of patients with biological recurrent
Summary
The widespread use of local and ablative treatment of oligometastatic prostate cancer outside the setting of clinical trials remains uncertain. Although there is a promising and growing bank of evidence, current standard of care has not been sufficiently challenged. There remain insufficient conclusions regarding cancer-specific and overall survival and the outcomes of the prospective trials are eagerly awaited.
Standardization in the definition of oligometastasis must extend beyond the number
References (63)
- et al.
The multistep nature of cancer
Trends Genet
(1993) - et al.
Cancer metastasis: building a framework
Cell
(2006) - et al.
Is there a favorable subset of patients with prostate cancer who develop oligometastases?
Int J Radiat Oncol Biol Phys
(2004) - et al.
EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent–update 2013
Eur Urol
(2014) - et al.
The impact of definitive local therapy for lymph node-positive prostate cancer: a population-based study
Int J Radiat Oncol Biol Phys
(2014) - et al.
Solitary metastases: illusion versus reality
Semin Radiat Oncol
(2006) - et al.
PET in prostate and bladder tumors
Semin Nucl Med
(2012) - et al.
Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis
Eur Urol
(2016) - et al.
Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trial
Radiother Oncol
(2016) - et al.
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
Ann Oncol
(2015)
Radical prostatectomy in the management of localized prostate cancer
Eur J Surg Oncol
Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study
J Urol
A Pilot Study of a Multimodal Treatment Paradigm to Accelerate Drug Evaluations in Early-stage Metastatic Prostate Cancer Urology
Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy
Clin Genitourin Cancer
“Gotta catch 'em all”, or do we? Pokemet approach to metastatic prostate cancer
Eur Urol
Impact of radical prostatectomy on long-term oncologic outcomes in a matched cohort of men with pathological node positive prostate cancer managed by castration
J Urol
Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer
Urology
Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era
J Urol
Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy
Eur Urol
Impact of previous local treatment for prostate cancer on subsequent metastatic disease
J Urol
The impact of prior radical prostatectomy in men with metastatic castration recurrent prostate cancer: a pooled analysis of 9 cancer and leukemia group B trials
J Urol
Treatment of the primary tumor in metastatic prostate cancer: current concepts and future perspectives
Eur Urol
Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study
Eur Urol
Role of radical prostatectomy in metastatic prostate cancer: data from the Munich Cancer Registry
Eur Urol
A multi-institutional analysis of perioperative outcomes in 106 men who underwent radical prostatectomy for distant metastatic prostate cancer at presentation
Eur Urol
Comparison of NaF and FDG PET/CT for assessment of treatment response in castration-resistant prostate cancers with osseous metastases
Clin Genitourin Cancer
Diagnostic efficacy of gallium-PSMA positron emission tomography compared to conventional imaging in lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer
J Urol
Impact of age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysis
Eur Urol
Oligometastases
J Clin Oncol
Molecular and cellular changes associated with the acquisition of metastatic ability by prostatic cancer cells
Prostate
Is cancer a disease of self-seeding?
Nat Med
Cited by (12)
Curative Lung Metastasectomy Without Concomitant Androgen Deprivation Therapy in Oligometastatic Castration-resistant Prostate Cancer: A Case Report and Review of the Literature
2020, Clinical Genitourinary CancerCitation Excerpt :In patients with oligometastatic disease by breast, kidney, lung, or colorectal neoplasms, ablative surgery or radiation therapy may be potentially curative, sometimes in association with adjuvant systemic treatments.4 Conversely, in patients with oligometastatic PC, ablative treatments are currently not indicated, except for clinical trials.5-7 In these patients, androgen deprivation therapy (ADT), achieved with surgical bilateral orchiectomy or luteinising hormone-releasing hormone (LHRH) agonist/antagonist, is still the standard treatment, according to international guidelines.7,8
Might definitive local therapy of the primary tumor improve the survival benefits of metastatic prostate cancer?-evidence from a meta-analysis
2020, Annals of Cardiothoracic SurgeryPSMA PET applications in the prostate cancer journey: from diagnosis to theranostics
2019, World Journal of Urology
Disclosures: None.